Aska to sell Sosei emergency contraceptive in Japan
This article was originally published in Scrip
Executive Summary
Aska Pharmaceutical is to undertake the sales and marketing of Sosei's oral emergency contraceptive Norlevo (SOH-075) in Japan, its home market. The agreement will see Sosei keep responsibility for the development and registration of the levonorgestrel-only product, which should be filed in the first half of next year and stands to become the first of its type in Japan. It is used to prevent unwanted pregnancy when administered within 72 hours of unprotected intercourse. Sosei originally acquired exclusive Japanese distribution rights from originator HRA Pharma, and will receive undisclosed upfront and milestone payments and a percentage of net sales from Aska. Aska already markets several oral contraceptives and fertility drugs and has acquired an equity stake in Sosei as part of the tie-up.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Teva’s immunology biosimilar launches; Intra-Cellular’s promising depression data; Phase III sleep apnea win for Lilly’s tirzepatide; an interview with Viking’s CEO; and China looks to define innovative drugs.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.